2 weeks Ago By Defense World Staff
Altimmune, Inc. ( NASDAQ:ALT – Get Free Report ) has been assigned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company.
The average 1-year price objective among analysts that have issued a report on the stock in the last year is $18.80. A number of equities analysts have recently weighed in on ALT shares.
HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Thursday, August 22nd. Piper Sandler reissued an “overweight” rating and issued a $25.
00 price objective on shares of Altimmune in a research report on Friday, June 21st. Evercore ISI raised Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. Finally, B.
Riley reissued a “buy” rating and issued a $20.00 price target on shares of Altimmune in a report on Monday, August 12th. Read Our Latest Analysis on Altimmune Insider Buying and Selling at Altimmune Institutional Trading of Altimmune A number of institutional investors have recently modified their holdings of ALT.
Farallon Capital Management LLC lifted its stake in Altimmune by 1,282.4% in the 1st quarter. Farallon Capital Management LLC now owns 470,000 shares of the company’s stock worth $4,785,000 after purchasing an additional 436,000 shares in the last quarter.
Lighthouse Investment Partners LLC bought a new stake in shares of Altimmune in the fourth quarter worth about $4,493,000. Knoll Capital Management LLC increased its holdings in Altimmune by 183.6% during the 1st quarter.
Knoll Capital Management LLC now owns 567,219 shares of the company’s stock valued at $5,774,000 after purchasing an additional 367,219 shares during the period. Dimensional Fund Advisors LP raised its position in Altimmune by 142.9% during the 2nd quarter.
Dimensional Fund Advisors LP now owns 570,174 shares of the company’s stock valued at $3,791,000 after purchasing an additional 335,444 shares during the last quarter. Finally, Gerber LLC purchased a new stake in Altimmune in the 4th quarter worth approximately $2,878,000. 78.
05% of the stock is currently owned by hedge funds and other institutional investors. Altimmune Stock Performance Shares of ALT opened at $6.47 on Friday.
The firm has a market capitalization of $458.74 million, a P/E ratio of -4.07 and a beta of 0.
08. Altimmune has a 52 week low of $2.09 and a 52 week high of $14.
84. The stock has a 50 day moving average price of $6.68 and a two-hundred day moving average price of $7.
28. Altimmune ( NASDAQ:ALT – Get Free Report ) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.
35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01).
Altimmune had a negative return on equity of 53.09% and a negative net margin of 24,778.97%.
The company had revenue of $0.01 million for the quarter. During the same period in the prior year, the business earned ($0.
32) EPS. On average, equities analysts forecast that Altimmune will post -0.54 earnings per share for the current year.
About Altimmune ( Get Free Report Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. Recommended Stories Five stocks we like better than Altimmune Investing in the High PE Growth Stocks CarMax’s Impressive Rally: What Investors Should Watch Next What Makes a Stock a Good Dividend Stock? MarketBeat Week in Review – 9/23 – 9/27 How to Choose Top Rated Stocks Wake Up to This Biotech Stock That Still Has Big Potential Upside Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.
com's FREE daily email newsletter ..
